drugset / Trial / NCT04425655
Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.
NaSingle-groupOpen-labelTreatment
Summary
This phase 2 clinical trial will evaluate the effectiveness and safety of fludarabine in combination with CPX-351 in patients with untreated AML. Patients will receive fludarabine and CPX-351 during Induction 1 and 2 as well as 2 cycles of consolidation therapy.
Timeline
- Start
- 2020-08-05
- Primary completion
- 2022-07-01
- Completion
- 2022-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CPX-351 | Other / unclassified | 65 mg/m2 | Intravenous |
| Subject | CPX-351 | Other / unclassified | 100 mg/m2 | Intravenous |
| Subject | Fludarabine | Small molecule | 30 mg/m2 | Intravenous |